Virologic Outcome at Week 48 - FDA Snapshot Analysis.
收藏数据链接：
官方服务：
资源简介：
Virologic Outcome at Week 48 - FDA Snapshot Analysis.
应用场景：
创建时间：
2015-12-02
相关数据集
Virologic response at the end of treatment and the end of follow-up.
*: 95% confidence interval (2-tailed) for the difference of response rate at week 44 between 60 ��g YIC and placebo groups was 1.5% to 24.1%; it was ?6.3% to 13.0% between 30 ��g YIC and placebo group
Figshare2015-12-02 更新50
Recurrent herpes labialis: developing drugs for treatment and prevention Recurrent herpes labialis: developing drugs for treatment and prevention
Collection: Health Policy and Services Research Series Title(s): Guidance for industry Contributor(s): United States. Department of Health and Human Services, issuing body. United States. Food and Dru
Digital Collections20
Dataset from An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
This open-label study will evaluate the safety and efficacy of co-formulated ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with or without ribavirin administered for
NIAID Data Ecosystem10
Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients
CELADEN was a randomized placebo-controlled trial of 50 patients with confirmed dengue fever to evaluate the efficacy and safety of celgosivir (A study registered at ClinicalTrials.gov, number NCT0161
NIAID Data Ecosystem40
Dataset from A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072 in hepatitis C vir
NIAID Data Ecosystem10
